Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.

Read the full article here

Related Articles